Bettina Steiner
Project Leader

Steiner

Bettina Steiner joined the project Phire as Project Leader in June 2022. In this function she is responsible for all business related activities as well as the development and manufacturing of the study medication. She has a track record of leading the Wyss Zurich project CeNeReg, where she is responsible for the manufacture of the study medication and supply for the phase II clinical study (NISCI). Prior to her role as Project Leader at Wyss Zurich, she worked in a contract development and manufacturing organization (CDMO). Through her previous roles, she has gained a comprehensive knowledge of antibody manufacturing and development (CLD, USP, DSP, QC, fill & finish, packaging) as well as quality aspects such as QM, GMP and regulatory affairs. She holds a Master’s degree in Pharmaceutical Biotechnology from Zurich University of Applied Sciences in Wädenswil (ZHAW) as well as a Certificate of Advanced Studies in Clinical Trial Management from University Hospital Zurich (USZ). In addition, she is currently finishing a Master's in Business Administration at the IU International University of Applied Sciences. She values open and clear communication, empathy, efficiency, teamwork and quality.

Contact:
bettina.steiner@wysszurich.ch
+41 44 634 56 87


Renier Myburgh
Scientific Lead

Myburgh

Renier Myburgh joined Wyss Zurich in July 2022 as Scientific Lead for the project Phire. In this function he is responsible for pharmacological and toxicological studies, as well as other research and development activities to develop the new products. Renier Myburgh is co-founder of two successful biotechnology companies, Transcure Bioservices and Antion Biosciences. Furthermore, he worked as a postdoctoral fellow on the development of CAR T-cells and therapeutic antibodies for hematological malignancies at the University Hospital Zurich. For his work in the field of gene therapy, he received his doctoral degree in natural sciences from University of Zurich. He also holds a Master of Research degree in Biosystematics from the Imperial College London. He is a highly motivated research scientist with considerable experience in design, management and supervision of biomedical research projects focused on translating gene therapy and cancer immunotherapy innovations to benefit patients.


17-09-21 - News

Phire Therapeutics wins Venture Kick's second stage support
read more

31-03-21 - Press Release

VentureKick - CHF 10,000 for antibodies for the treatment of Leukemia
read more

All News